首页 > 最新文献

Visceral Medicine最新文献

英文 中文
The Challenge of Anticoagulation in Liver Cirrhosis. 肝硬化患者抗凝治疗的挑战。
IF 1.8 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-21 DOI: 10.1159/000535438
Julia Carolin Eichholz, Heiner Wedemeyer, Benjamin Maasoumy

Background: Advanced liver diseases are characterized by a number of changes in the hemostatic system. Due to the occurrence of bleeding events in patients with liver cirrhosis, there seems to be a hesitance to the administration of anticoagulant medications. This review summarizes challenges, recommendations, and current developments of anticoagulation in the cirrhotic patient.

Summary: The risk of thrombotic events in patients with liver cirrhosis is at least as high as in patients with healthy liver function if not even higher. Standard laboratory markers do not truly reflect the complexity of changes that take place in the coagulative system and therefore cannot be used as a reference for risk of thrombosis or hemorrhage. Potential options for anticoagulant therapy are heparins, vitamin K antagonists, and direct-acting oral anticoagulants which come with differences in safety, application, possible side effects, and data availability for the patient cohort.

Key message: The administration of anticoagulation can be beneficial in patients with liver disease if the indication is present and bleeding prophylaxis has been established. Direct-acting oral anticoagulants appear to be a promising new approach with many improvements compared to conventional substances. Nevertheless, there is a need for further data and prospective trials on the use in patients with liver cirrhosis.

背景:晚期肝病的特点是止血系统发生一系列变化。由于肝硬化患者会发生出血事件,因此在使用抗凝药物时似乎有些犹豫不决。摘要:肝硬化患者发生血栓事件的风险至少与肝功能健康的患者一样高,甚至更高。标准实验室指标不能真实反映凝血系统发生的复杂变化,因此不能作为血栓形成或出血风险的参考。抗凝疗法的潜在选择包括肝素、维生素 K 拮抗剂和直接作用口服抗凝剂,这些药物在安全性、应用、可能的副作用以及患者群体的数据可用性方面存在差异:关键信息:如果肝病患者有适应症并已确立出血预防措施,服用抗凝药对患者有益。直接作用口服抗凝剂似乎是一种很有前景的新方法,与传统药物相比有很多改进。然而,在肝硬化患者中使用这种药物还需要更多的数据和前瞻性试验。
{"title":"The Challenge of Anticoagulation in Liver Cirrhosis.","authors":"Julia Carolin Eichholz, Heiner Wedemeyer, Benjamin Maasoumy","doi":"10.1159/000535438","DOIUrl":"10.1159/000535438","url":null,"abstract":"<p><strong>Background: </strong>Advanced liver diseases are characterized by a number of changes in the hemostatic system. Due to the occurrence of bleeding events in patients with liver cirrhosis, there seems to be a hesitance to the administration of anticoagulant medications. This review summarizes challenges, recommendations, and current developments of anticoagulation in the cirrhotic patient.</p><p><strong>Summary: </strong>The risk of thrombotic events in patients with liver cirrhosis is at least as high as in patients with healthy liver function if not even higher. Standard laboratory markers do not truly reflect the complexity of changes that take place in the coagulative system and therefore cannot be used as a reference for risk of thrombosis or hemorrhage. Potential options for anticoagulant therapy are heparins, vitamin K antagonists, and direct-acting oral anticoagulants which come with differences in safety, application, possible side effects, and data availability for the patient cohort.</p><p><strong>Key message: </strong>The administration of anticoagulation can be beneficial in patients with liver disease if the indication is present and bleeding prophylaxis has been established. Direct-acting oral anticoagulants appear to be a promising new approach with many improvements compared to conventional substances. Nevertheless, there is a need for further data and prospective trials on the use in patients with liver cirrhosis.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"39 6","pages":"169-176"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline Interleukin-6 as a Preoperative Biomarker for Liver Fibrosis. 作为肝纤维化术前生物标志物的基线白细胞介素-6
IF 1.8 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-27 DOI: 10.1159/000535627
Dominik Thomas Koch, Dionysios Koliogiannis, Moritz Drefs, Malte Schirren, Viktor von Ehrlich-Treuenstätt, Hanno Nieß, Bernhard Renz, Matthias Ilmer, Joachim Andrassy, Markus O Guba, Jens Werner, Florian Kühn

Introduction: Liver (hepatic) fibrosis (LF) is characterized by impaired function and regenerative capacity of the liver and can lead to significantly increased morbidity and mortality in the context of surgical liver resection (LR). For this reason, it is crucial to identify the extent of LF preoperatively. Interleukin-6 (IL-6) is known to play a key role in the pathogenesis of LF, but its exact value as a preoperative marker is unknown. This study aimed to investigate the correlation between preoperatively determined IL-6 and the presence of LF.

Methods: In this prospective study, IL-6 was determined in 134 consecutive patients undergoing LR. Patients with liver cirrhosis (LC) and patients with clinical or laboratory signs of inflammation were excluded. LF was graded by a blinded pathologist with regard to the degree of LF according to the Desmet classification (0-4). Baseline IL-6 and degree of LF were correlated.

Results: A total of 134 patients were prospectively included prior to LR. For 104 patients, LF was graded and inflammatory parameters were available. Thirty-five of these patients showed LC (Desmet 4), and another 33 patients showed preoperatively elevated inflammatory markers. Two of the remaining patients were liver transplant patients. These patients were excluded from the final analysis. According to Desmet, the remaining 34 patients had LF grade 0 or 1 (none or minimal LF) in 26 cases and LF grade 2 or 3 (moderate-to-severe LF) in 8 cases. Correlation of LF with preoperatively determined IL-6 yielded significantly higher IL-6 levels in the group of patients with moderate-to-severe LF (Desmet 2 or 3) compared to the group with none or minimal LF (Desmet 0 or 1; p = 0.0495).

Conclusion: In the context of LR, our results showed a correlation of preoperatively determined IL-6 with the extent of LF present. Higher serum baseline IL-6 concentrations were associated with a higher degree of LF, whereas no other blood parameter or score was that predictive for LF. Our results suggest that baseline IL-6 might serve as a valuable parameter to assess LF prior to LR. More patients need to be analyzed to further evaluate and confirm the predictive accuracy of IL-6 for LF.

导言:肝(肝)纤维化(LF)的特点是肝脏功能和再生能力受损,可导致手术肝切除(LR)的发病率和死亡率显著增加。因此,术前确定肝纤维化的程度至关重要。众所周知,白细胞介素-6(IL-6)在肝纤维化的发病机制中起着关键作用,但其作为术前标志物的确切价值尚不清楚。本研究旨在探讨术前测定的 IL-6 与 LF 存在之间的相关性:在这项前瞻性研究中,对 134 名连续接受 LR 的患者进行了 IL-6 测定。排除了肝硬化(LC)患者和有临床或实验室炎症迹象的患者。LF由盲法病理学家根据Desmet分类法(0-4)对LF程度进行分级。基线IL-6与LF程度相关:结果:共有 134 名患者在 LR 前接受了前瞻性研究。其中 104 例患者的 LF 已分级,炎症参数也已获得。其中 35 例患者出现低密度脂蛋白血症(Desmet 4),另有 33 例患者术前炎症指标升高。其余两名患者为肝移植患者。这些患者被排除在最终分析之外。根据 Desmet 的数据,其余 34 例患者中,26 例患者的 LF 等级为 0 或 1(无或轻度 LF),8 例患者的 LF 等级为 2 或 3(中度至重度 LF)。LF 与术前测定的 IL-6 的相关性显示,中重度 LF 患者组(Desmet 2 或 3)的 IL-6 水平明显高于无 LF 或轻度 LF 患者组(Desmet 0 或 1;P = 0.0495):我们的研究结果表明,在 LR 的情况下,术前测定的 IL-6 与 LF 的存在程度相关。较高的血清基线 IL-6 浓度与较高的 LF 程度相关,而其他血液参数或评分均不能预测 LF。我们的研究结果表明,基线 IL-6 可能是在 LR 之前评估 LF 的一个有价值的参数。需要对更多患者进行分析,以进一步评估和确认 IL-6 对 LF 的预测准确性。
{"title":"Baseline Interleukin-6 as a Preoperative Biomarker for Liver Fibrosis.","authors":"Dominik Thomas Koch, Dionysios Koliogiannis, Moritz Drefs, Malte Schirren, Viktor von Ehrlich-Treuenstätt, Hanno Nieß, Bernhard Renz, Matthias Ilmer, Joachim Andrassy, Markus O Guba, Jens Werner, Florian Kühn","doi":"10.1159/000535627","DOIUrl":"10.1159/000535627","url":null,"abstract":"<p><strong>Introduction: </strong>Liver (hepatic) fibrosis (LF) is characterized by impaired function and regenerative capacity of the liver and can lead to significantly increased morbidity and mortality in the context of surgical liver resection (LR). For this reason, it is crucial to identify the extent of LF preoperatively. Interleukin-6 (IL-6) is known to play a key role in the pathogenesis of LF, but its exact value as a preoperative marker is unknown. This study aimed to investigate the correlation between preoperatively determined IL-6 and the presence of LF.</p><p><strong>Methods: </strong>In this prospective study, IL-6 was determined in 134 consecutive patients undergoing LR. Patients with liver cirrhosis (LC) and patients with clinical or laboratory signs of inflammation were excluded. LF was graded by a blinded pathologist with regard to the degree of LF according to the Desmet classification (0-4). Baseline IL-6 and degree of LF were correlated.</p><p><strong>Results: </strong>A total of 134 patients were prospectively included prior to LR. For 104 patients, LF was graded and inflammatory parameters were available. Thirty-five of these patients showed LC (Desmet 4), and another 33 patients showed preoperatively elevated inflammatory markers. Two of the remaining patients were liver transplant patients. These patients were excluded from the final analysis. According to Desmet, the remaining 34 patients had LF grade 0 or 1 (none or minimal LF) in 26 cases and LF grade 2 or 3 (moderate-to-severe LF) in 8 cases. Correlation of LF with preoperatively determined IL-6 yielded significantly higher IL-6 levels in the group of patients with moderate-to-severe LF (Desmet 2 or 3) compared to the group with none or minimal LF (Desmet 0 or 1; <i>p</i> = 0.0495).</p><p><strong>Conclusion: </strong>In the context of LR, our results showed a correlation of preoperatively determined IL-6 with the extent of LF present. Higher serum baseline IL-6 concentrations were associated with a higher degree of LF, whereas no other blood parameter or score was that predictive for LF. Our results suggest that baseline IL-6 might serve as a valuable parameter to assess LF prior to LR. More patients need to be analyzed to further evaluate and confirm the predictive accuracy of IL-6 for LF.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"39 6","pages":"184-192"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbiota Manipulation as an Emerging Concept in Cancer Therapy 操纵微生物群是癌症治疗的新概念
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-12 DOI: 10.1159/000534810
M. Spalinger, Michael Scharl
Background: The human body is colonized by billions of bacteria that provide nutrients to the host, train our immune system, and importantly affect our heath. It has long been suggested that microbes might play a role in tumor pathogenesis; however, compelling evidence was only provided in the past decades when novel detection methods that do not depend on culturing techniques had been developed. Summary: The microbiome impacts tumor development and anti-tumor therapies on various levels. Bacteria can promote or suppress tumor growth via direct interactions with cancer cells, production of metabolites that promote or inhibit tumor growth, and via stimulation or suppression of the local and systemic immune response. Cancer patients harbor a distinct microbiome when compared to healthy controls, which could potentially be employed to detect, identify, and treat cancer. Manipulation of the microbiome either via supplementation of single strains, bacterial consortia, fecal microbiota transfer or the use of pre- and probiotics has been suggested as therapeutic approach to directly target tumor growth or to enhance the efficacy of current state-of-the-art treatment options. Key Messages: (1) Bacteria have a tremendous impact on anti-cancer immune responses. (2) Cancer patients harbor a distinct microbiome when compared to healthy controls. (3) The microbiome seems to be cancer-type specific. (4) Exploitation of bacteria to promote anti-tumor therapy is a novel, very promising venue in cancer treatment.
背景:人体内有数十亿个细菌,它们为宿主提供营养,训练我们的免疫系统,并对我们的健康产生重要影响。长期以来,人们一直认为微生物可能在肿瘤发病机制中发挥作用;然而,直到过去几十年中,不依赖培养技术的新型检测方法被开发出来,才提供了令人信服的证据。摘要:微生物组在不同层面上影响着肿瘤的发展和抗肿瘤疗法。细菌可通过与癌细胞的直接相互作用、产生促进或抑制肿瘤生长的代谢物以及刺激或抑制局部和全身免疫反应来促进或抑制肿瘤生长。与健康对照组相比,癌症患者体内的微生物组截然不同,这有可能被用来检测、识别和治疗癌症。有人建议通过补充单一菌株、细菌联合体、粪便微生物群转移或使用预益生菌和益生菌来操纵微生物群,作为直接针对肿瘤生长或提高当前最先进治疗方案疗效的治疗方法。关键信息:(1)细菌对抗癌免疫反应有巨大影响。(2)与健康对照组相比,癌症患者体内的微生物组截然不同。(3)微生物组似乎具有癌症类型特异性。(4)利用细菌促进抗肿瘤治疗是癌症治疗中一个非常有前景的新领域。
{"title":"Microbiota Manipulation as an Emerging Concept in Cancer Therapy","authors":"M. Spalinger, Michael Scharl","doi":"10.1159/000534810","DOIUrl":"https://doi.org/10.1159/000534810","url":null,"abstract":"Background: The human body is colonized by billions of bacteria that provide nutrients to the host, train our immune system, and importantly affect our heath. It has long been suggested that microbes might play a role in tumor pathogenesis; however, compelling evidence was only provided in the past decades when novel detection methods that do not depend on culturing techniques had been developed. Summary: The microbiome impacts tumor development and anti-tumor therapies on various levels. Bacteria can promote or suppress tumor growth via direct interactions with cancer cells, production of metabolites that promote or inhibit tumor growth, and via stimulation or suppression of the local and systemic immune response. Cancer patients harbor a distinct microbiome when compared to healthy controls, which could potentially be employed to detect, identify, and treat cancer. Manipulation of the microbiome either via supplementation of single strains, bacterial consortia, fecal microbiota transfer or the use of pre- and probiotics has been suggested as therapeutic approach to directly target tumor growth or to enhance the efficacy of current state-of-the-art treatment options. Key Messages: (1) Bacteria have a tremendous impact on anti-cancer immune responses. (2) Cancer patients harbor a distinct microbiome when compared to healthy controls. (3) The microbiome seems to be cancer-type specific. (4) Exploitation of bacteria to promote anti-tumor therapy is a novel, very promising venue in cancer treatment.","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"33 21","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139008976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Open-Pore Film Drainage Systems in Endoscopic Vacuum Therapy: Current Status and Review of the Literature 开孔膜引流系统在内窥镜真空治疗中的作用:现状与文献综述
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-11 DOI: 10.1159/000535029
Konstantinos Kouladouros, Dörte Wichmann, Gunnar Loske
Background: Endoscopic vacuum therapy (EVT) is an increasingly popular endoscopic technique used for the treatment of wall defects in the gastrointestinal tract. Open-pore film drainage (OFD) systems are a new addition to the armamentarium of EVT and have shown encouraging results in a wide spectrum of applications. The aim of this review is to summarize the current literature on the applications of OFD systems in the gastrointestinal tract. Summary: Open-pore film drainage (OFD) systems have been used for the treatment of several defects of the gastrointestinal tract. The small size and easy placement of these devices make them very useful, particularly for the treatment of defects that are small in size or difficult to reach. OFDs have been successfully used for both perforations and anastomotic leaks in various locations, with most reports focusing on the treatment of duodenal defects, although successful applications in the esophagus, stomach, and colon have also been reported. Lately, the role of OFDs in preemptive EVT has also been explored. Key Messages: OFD systems are easy to use, particularly for small defects and challenging localizations. The current literature, consisting mainly of small case series and case reports, shows encouraging results, but further prospective studies are needed to explore and verify the indications and technical aspects of this innovative method.
背景:内窥镜真空治疗(EVT)是一种日益流行的内窥镜技术,用于治疗胃肠道壁缺损。开孔膜引流(OFD)系统是 EVT 的新成员,在广泛的应用中取得了令人鼓舞的效果。本综述旨在总结目前有关胃肠道开孔膜引流系统应用的文献。摘要:开孔薄膜引流系统(OFD)已被用于治疗多种胃肠道缺损。这些设备体积小、易于放置,因此非常有用,尤其是在治疗体积小或难以触及的缺损时。OFD 已成功用于治疗不同部位的穿孔和吻合口漏,大多数报道都集中在十二指肠缺损的治疗上,但也有成功应用于食道、胃和结肠的报道。最近,人们还探索了 OFD 在先期 EVT 中的作用。关键信息:OFD 系统易于使用,尤其适用于小缺损和具有挑战性的定位。目前的文献主要由小型病例系列和病例报告组成,显示了令人鼓舞的结果,但还需要进一步的前瞻性研究来探索和验证这种创新方法的适应症和技术方面。
{"title":"The Role of Open-Pore Film Drainage Systems in Endoscopic Vacuum Therapy: Current Status and Review of the Literature","authors":"Konstantinos Kouladouros, Dörte Wichmann, Gunnar Loske","doi":"10.1159/000535029","DOIUrl":"https://doi.org/10.1159/000535029","url":null,"abstract":"Background: Endoscopic vacuum therapy (EVT) is an increasingly popular endoscopic technique used for the treatment of wall defects in the gastrointestinal tract. Open-pore film drainage (OFD) systems are a new addition to the armamentarium of EVT and have shown encouraging results in a wide spectrum of applications. The aim of this review is to summarize the current literature on the applications of OFD systems in the gastrointestinal tract. Summary: Open-pore film drainage (OFD) systems have been used for the treatment of several defects of the gastrointestinal tract. The small size and easy placement of these devices make them very useful, particularly for the treatment of defects that are small in size or difficult to reach. OFDs have been successfully used for both perforations and anastomotic leaks in various locations, with most reports focusing on the treatment of duodenal defects, although successful applications in the esophagus, stomach, and colon have also been reported. Lately, the role of OFDs in preemptive EVT has also been explored. Key Messages: OFD systems are easy to use, particularly for small defects and challenging localizations. The current literature, consisting mainly of small case series and case reports, shows encouraging results, but further prospective studies are needed to explore and verify the indications and technical aspects of this innovative method.","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"43 3","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138979299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbiota Therapy: Ready for Clinical Practice? 微生物群疗法:准备好临床实践了吗?
4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-11-14 DOI: 10.1159/000534778
Michael Scharl, Gerhard Rogler
{"title":"Microbiota Therapy: Ready for Clinical Practice?","authors":"Michael Scharl, Gerhard Rogler","doi":"10.1159/000534778","DOIUrl":"https://doi.org/10.1159/000534778","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"15 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134955340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interdisciplinary Frontiers – The View of Surgery 跨学科的前沿-外科的观点
4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-27 DOI: 10.1159/000533743
Pompiliu Piso, Maximilian Babucke, Vanessa Schmitt, Sebastian Blaj
{"title":"Interdisciplinary Frontiers – The View of Surgery","authors":"Pompiliu Piso, Maximilian Babucke, Vanessa Schmitt, Sebastian Blaj","doi":"10.1159/000533743","DOIUrl":"https://doi.org/10.1159/000533743","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"25 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136233982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydatid Disease of the Liver. 肝棘球蚴病。
IF 1.8 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-09-25 DOI: 10.1159/000533807
Virandera Pal Bhalla, Souvik Paul, Ernst Klar

Background: Echinococcosis also known as hydatid disease is a zoonotic parasitic disease caused by a tapeworm. It has a worldwide distribution. For long, it was thought to be a problem of the poorly sanitized "third world" and not given the importance it deserved. However, its occurrence in countries like Australia and New Zealand and recently in countries in Central Europe has meant that it is included in a WHO list of neglected diseases, has recently been the subject of extensive epidemiological studies, and has been the recipient of increased research funding.

Summary: The diagnosis is still based on clinical presentation in an endemic area corroborated with typical findings on imaging which routinely include ultrasound and CT scan. Serological tests have been used in some centers to support the diagnosis. Treatment depends on the site of involvement and can vary from wait and watch to extensive radical surgical procedures. The common element of all treatments is the addition of albendazole which forms an essential cornerstone of all treatment protocols. Inspite having been used for a fairly long time, there is still no consensus on the dose, duration, and timing of therapy with albendazole.

Key message: Hydatid disease continues to be a significant global health problem inspite of a good understanding of its life cycle and rising standards of public sanitation. Though diagnosis is straightforward and not expensive, treatment can sometimes be complicated. The addition of albendazole to all treatment protocols is an important advance, but firm guidelines on duration of its use are still awaited.

背景:棘球蚴病又称棘球蚴症,是一种由绦虫引起的人畜共患寄生虫病。它在全球范围内发行。长期以来,这被认为是“第三世界”消毒不力的问题,没有得到应有的重视。然而,它在澳大利亚和新西兰等国以及最近在中欧国家的出现意味着它被列入世界卫生组织被忽视疾病名单,最近成为广泛流行病学研究的主题,并获得了更多的研究资金。总结:诊断仍然基于流行地区的临床表现,并与常规包括超声和CT扫描在内的典型成像结果相证实。一些中心已经使用血清学测试来支持诊断。治疗取决于涉及的部位,从等待和观察到广泛的根治性手术都有可能。所有治疗的共同因素是添加阿苯达唑,这是所有治疗方案的重要基石。尽管阿苯达唑已经使用了相当长的时间,但在剂量、持续时间和治疗时间方面仍然没有达成共识。关键信息:尽管人们对棘球蚴病的生命周期有很好的了解,而且公共卫生标准不断提高,但它仍然是一个重大的全球健康问题。尽管诊断简单且不昂贵,但治疗有时可能很复杂。在所有治疗方案中加入阿苯达唑是一个重要的进展,但关于其使用期限的确切指导方针仍在等待中。
{"title":"Hydatid Disease of the Liver.","authors":"Virandera Pal Bhalla, Souvik Paul, Ernst Klar","doi":"10.1159/000533807","DOIUrl":"10.1159/000533807","url":null,"abstract":"<p><strong>Background: </strong>Echinococcosis also known as hydatid disease is a zoonotic parasitic disease caused by a tapeworm. It has a worldwide distribution. For long, it was thought to be a problem of the poorly sanitized \"third world\" and not given the importance it deserved. However, its occurrence in countries like Australia and New Zealand and recently in countries in Central Europe has meant that it is included in a WHO list of neglected diseases, has recently been the subject of extensive epidemiological studies, and has been the recipient of increased research funding.</p><p><strong>Summary: </strong>The diagnosis is still based on clinical presentation in an endemic area corroborated with typical findings on imaging which routinely include ultrasound and CT scan. Serological tests have been used in some centers to support the diagnosis. Treatment depends on the site of involvement and can vary from wait and watch to extensive radical surgical procedures. The common element of all treatments is the addition of albendazole which forms an essential cornerstone of all treatment protocols. Inspite having been used for a fairly long time, there is still no consensus on the dose, duration, and timing of therapy with albendazole.</p><p><strong>Key message: </strong>Hydatid disease continues to be a significant global health problem inspite of a good understanding of its life cycle and rising standards of public sanitation. Though diagnosis is straightforward and not expensive, treatment can sometimes be complicated. The addition of albendazole to all treatment protocols is an important advance, but firm guidelines on duration of its use are still awaited.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"39 5","pages":"112-120"},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Value of Clip-and-Snare Assisted Endoscopic Submucosal Resection in Treatment of Rectal Neuroendocrine Tumors. 钳夹和圈套辅助内镜下黏膜下切除术治疗直肠神经内分泌肿瘤的临床价值。
IF 1.8 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-09-05 DOI: 10.1159/000533393
Xin-Tong Jiang, Yang Hu, Jian Gong, Shi-Bin Guo

Introduction: The aim of the study was to introduce a new endoscopic technology, clip-and-snare assisted endoscopic submucosal resection (CS-ESMR), for treatment of rectal neuroendocrine tumors (NETs) and then to investigate the therapeutic value of CS-ESMR.

Methods: In this retrospective study, 67 patients who underwent endoscopic treatment of rectal NETs from March 2017 to December 2021 were analyzed. According to the endoscopic resection methods (endoscopic mucosal resection [EMR], CS-ESMR, and endoscopic submucosal dissection [ESD]), the cases were divided into CS-ESMR group (27 cases), ESD group (31 cases), and EMR group (9 cases). The pathological R0 resection rate and the incidence of adverse events (bleeding and perforation) were compared among the three groups.

Results: There was a significant difference about the pathological R0 resection between the CS-ESMR group and the EMR group and between the CS-ESMR group and the ESD group (both p < 0.05). Compared with ESD group, the procedure time, intraoperative bleeding, and the cost of CS-ESMR group are significantly decreased (p < 0.001, p < 0.05, p < 0.001, respectively).

Conclusion: CS-ESMR may be a safe and effective treatment for rectal NETs with a diameter of less than 10 mm, without muscularis propria invasion and metastasis.

引言:本研究的目的是介绍一种新的内镜技术,即夹套辅助内镜黏膜下切除术(CS-ESMR),用于治疗直肠神经内分泌肿瘤(NETs),然后探讨CS-ESMR的治疗价值。方法:在本回顾性研究中,对2017年3月至2021年12月接受直肠NETs内镜治疗的67名患者进行了分析。根据内镜切除方法(内镜黏膜切除[ERR]、CS-ESMR和内镜黏膜下剥离[ESD]),将病例分为CS-ESMR组(27例)、ESD组(31例)和EMR组(9例)。比较三组的病理R0切除率和不良事件(出血和穿孔)的发生率。结果:CS-ESMR组与EMR组及CS-ESMR与ESD组在病理性R0切除方面有显著性差异(均p<0.05),结论:CS-ESMR治疗直径小于10mm、无固有肌层浸润和转移的直肠NETs是一种安全有效的治疗方法。
{"title":"Clinical Value of Clip-and-Snare Assisted Endoscopic Submucosal Resection in Treatment of Rectal Neuroendocrine Tumors.","authors":"Xin-Tong Jiang, Yang Hu, Jian Gong, Shi-Bin Guo","doi":"10.1159/000533393","DOIUrl":"10.1159/000533393","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to introduce a new endoscopic technology, clip-and-snare assisted endoscopic submucosal resection (CS-ESMR), for treatment of rectal neuroendocrine tumors (NETs) and then to investigate the therapeutic value of CS-ESMR.</p><p><strong>Methods: </strong>In this retrospective study, 67 patients who underwent endoscopic treatment of rectal NETs from March 2017 to December 2021 were analyzed. According to the endoscopic resection methods (endoscopic mucosal resection [EMR], CS-ESMR, and endoscopic submucosal dissection [ESD]), the cases were divided into CS-ESMR group (27 cases), ESD group (31 cases), and EMR group (9 cases). The pathological R0 resection rate and the incidence of adverse events (bleeding and perforation) were compared among the three groups.</p><p><strong>Results: </strong>There was a significant difference about the pathological R0 resection between the CS-ESMR group and the EMR group and between the CS-ESMR group and the ESD group (both <i>p</i> < 0.05). Compared with ESD group, the procedure time, intraoperative bleeding, and the cost of CS-ESMR group are significantly decreased (<i>p</i> < 0.001, <i>p</i> < 0.05, <i>p</i> < 0.001, respectively).</p><p><strong>Conclusion: </strong>CS-ESMR may be a safe and effective treatment for rectal NETs with a diameter of less than 10 mm, without muscularis propria invasion and metastasis.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"39 5","pages":"140-147"},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Ultrasound in Pancreatology: Focus on Inflammatory Diseases and Interventions. 胰腺科的内镜超声:聚焦炎症性疾病和介入治疗。
IF 1.8 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-09-05 DOI: 10.1159/000533433
Francesco Vitali, Sebastian Zundler, Daniel Jesper, Deike Strobel, Dane Wildner, Nicoló de Pretis, Luca Frulloni, Stefano Francesco Crinó, Markus F Neurath

Background: Endoscopic ultrasound (EUS) is a main tool in pancreatology for both diagnosis and therapy. It allows minimally invasive differentiation of various diseases, with a minimal degree of inflammation or anatomic variations. EUS also enables interventional direct access to the pancreatic parenchyma and the retroperitoneal space, the pancreatic duct, the pancreatic masses, cysts, vascular structures for diagnostic and therapeutic purposes.

Summary: This review aimed to summarize the new developments of EUS in the field of pancreatology, with special interest on inflammation and interventions. EUS enables way to perform pseudocyst drainage, necrosectomy, transenteral drainage and transenteric access of the main pancreatic duct, or the direct visualization or therapy of vascular structures adjacent to the pancreas.

Key messages: EUS has a deep impact on pancreatology, and the development of new diagnostic and interventional approaches to the retroperitoneal space and the pancreas has increased in the last years exponentially, allowing minimal invasive diagnostics and therapy and avoiding surgery and percutaneous therapy.

背景:内镜超声(EUS)是胰腺科诊断和治疗的主要工具。它允许以最小程度的炎症或解剖变异对各种疾病进行微创分化。EUS还能够介入直接进入胰腺实质和腹膜后间隙、胰管、胰腺肿块、囊肿、血管结构,用于诊断和治疗目的。综述:本综述旨在总结EUS在胰腺学领域的新进展,特别关注炎症和干预措施。EUS能够进行假性囊肿引流、坏死切除术、经肠引流和经肠进入主胰管,或直接观察或治疗胰腺附近的血管结构。关键信息:EUS对胰腺学有着深刻的影响,在过去几年中,腹膜后间隙和胰腺的新诊断和介入方法的发展呈指数级增长,允许微创诊断和治疗,避免手术和经皮治疗。
{"title":"Endoscopic Ultrasound in Pancreatology: Focus on Inflammatory Diseases and Interventions.","authors":"Francesco Vitali, Sebastian Zundler, Daniel Jesper, Deike Strobel, Dane Wildner, Nicoló de Pretis, Luca Frulloni, Stefano Francesco Crinó, Markus F Neurath","doi":"10.1159/000533433","DOIUrl":"10.1159/000533433","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic ultrasound (EUS) is a main tool in pancreatology for both diagnosis and therapy. It allows minimally invasive differentiation of various diseases, with a minimal degree of inflammation or anatomic variations. EUS also enables interventional direct access to the pancreatic parenchyma and the retroperitoneal space, the pancreatic duct, the pancreatic masses, cysts, vascular structures for diagnostic and therapeutic purposes.</p><p><strong>Summary: </strong>This review aimed to summarize the new developments of EUS in the field of pancreatology, with special interest on inflammation and interventions. EUS enables way to perform pseudocyst drainage, necrosectomy, transenteral drainage and transenteric access of the main pancreatic duct, or the direct visualization or therapy of vascular structures adjacent to the pancreas.</p><p><strong>Key messages: </strong>EUS has a deep impact on pancreatology, and the development of new diagnostic and interventional approaches to the retroperitoneal space and the pancreas has increased in the last years exponentially, allowing minimal invasive diagnostics and therapy and avoiding surgery and percutaneous therapy<i>.</i></p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"39 5","pages":"131-139"},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parasitic Disease of the Gastrointestinal Tract: Surgical Aspects. 胃肠道寄生虫病:外科方面。
IF 1.8 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-01 Epub Date: 2023-09-15 DOI: 10.1159/000533352
Ernst Klar
{"title":"Parasitic Disease of the Gastrointestinal Tract: Surgical Aspects.","authors":"Ernst Klar","doi":"10.1159/000533352","DOIUrl":"10.1159/000533352","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"39 5","pages":"111"},"PeriodicalIF":1.8,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Visceral Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1